Clinical Research Directory
Browse clinical research sites, groups, and studies.
Tucatinib Continuation Study
Sponsor: Pfizer
Summary
The purpose of this protocol is to give continued access to tucatinib eligible participants. It also enables ongoing safety follow-up for those who continue to benefit from the study treatment. These participants were part of Pfizer-sponsored tucatinib parent studies that will be closed. Additional follow-up safety information will be collected. This will allow further understanding of the safety profile of tucatinib in participants who continue to receive the study treatment.
Official title: TUCATINIB CONTINUATION PROTOCOL: AN OPEN-LABEL STUDY FOR PARTICIPANTS FROM TUCATINIB CLINICAL STUDIES
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
175
Start Date
2026-11-06
Completion Date
2032-03-13
Last Updated
2026-08-28
Healthy Volunteers
No
Conditions
Interventions
tucatinib
150 - 300 mg, by mouth, twice a day